Opportunities for Healthy Volunteers

Contribute to medical research by participating in studies designed for healthy participants in your selected area.

Matched clinical trials

  • Study of enzalutamide alone versus enzalutamide with radium-223 combination in patients with bone metastatic castration-resistant prostate cancer with mild or no symptoms

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    Belgium Denmark France Ireland Italy Norway +2
  • Study of Pembrolizumab, Carboplatin, and Cabazitaxel for Patients with Aggressive Metastatic Castration-Resistant Prostate Cancer

    Not recruiting

    2 1 1 1
    Spain
  • Study of Pembrolizumab and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

    Not recruiting

    3 1 1
    Austria Bulgaria Czechia France Germany Hungary +5
  • Study Comparing Docetaxel, Darolutamide, and ADT for Patients with Metastatic Hormone-Sensitive Prostate Cancer

    Not recruiting

    3 1 1 1
    Austria Germany
  • Study on Darolutamide and Androgen Deprivation Therapy for Men with Metastatic Hormone-Sensitive Prostate Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    Investigated Drugs:
    Latvia Lithuania Spain
  • Study of Nivolumab, Ipilimumab, or Cabazitaxel for Men with Advanced Prostate Cancer Resistant to Hormone Therapy

    Not recruiting

    2 1 1 1
    Germany
  • Study on Talazoparib and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

    Not recruiting

    3 1 1
    Investigated Drugs:
    Belgium Czechia Finland France Germany Hungary +6